Skip to main content
FDA grants Fast Track status to fosmanogepix's oral, IV formulations
9/11/2019

Fast Track designations were granted by the FDA for the oral and intravenous formulations of Amplyx Pharmaceuticals' fosmanogepix, or APX001. The antifungal can be used as a treatment for seven indications, which include coccidioidomycosis, cryptococcosis, fusariosis, invasive aspergillosis, invasive candidiasis, mucormycosis, and scedosporiosis.

Full Story: